Authors: KIRCHGASSLER KU SCHMITZ H BACH G

Citation: Ku. Kirchgassler et al., EFFECTIVENESS AND TOLERABILITY OF 12-WEEK TREATMENT WITH MICRONIZED FENOFIBRATE 200MG IN A DRUG-MONITORING PROGRAM INVOLVING 9884 PATIENTS WITH DYSLIPIDEMIA, Clinical drug investigation, 15(3), 1998, pp. 197-204

Authors: KIRCHGASSLER KU SCHIFFNERROHE J STAHLHEBER U

Citation: Ku. Kirchgassler et al., COST-EFFECTIVENESS OF MICRONIZED FENOFIBRATE AND SIMVASTATIN IN THE SHORT-TERM TREATMENT OF TYPE IIA AND TYPE IIB HYPERLIPIDEMIA, PharmacoEconomics, 12(2), 1997, pp. 237-246

Authors: KIRCHGASSLER KU STAHLHEBER U VIERGUTZ S

Citation: Ku. Kirchgassler et al., CROSS-COUNTRY ADAPTATION OF PHARMACO-ECONOMIC EVALUATIONS - THE EXAMPLE OF MICRONIZED FENOFIBRATE AND SIMVASTATIN, Atherosclerosis, 134(1-2), 1997, pp. 52-52

Authors: SU CAPF VANHEININGEN PNM VANLIER JJ DEBRUIN H KIRCHGASSLER KU CORNELISSEN PJG JONKMAN JHG

Citation: Capf. Su et al., PHARMACODYNAMICS OF THE A-II ANTAGONIST BIBR0277SE, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 205-205